Baird served as a lead manager on this offering
AboutApellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ-GS: APLS) recently completed an underwritten public offering of 10,925,000 shares of its common stock at a price to the public of $37.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,425,000 shares of common stock. The gross proceeds to Apellis from the offering are expected to be approximately $404.2 million.
Apellis is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, Apellis aims to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology and nephrology. Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
CONTACT US TO LEARN MORE
- January 2020
- Apellis Pharmaceuticals, Inc.
- Target Location
- North America